Arvind Kush Purchases 145,000 Shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) Stock

Inhibikase Therapeutics, Inc. (NYSE:IKT) Director Arvind Kush bought 145,000 shares of the stock in a transaction on Monday, October 21st. The stock was acquired at an average cost of $1.37 per share, for a total transaction of $198,650.00. Following the acquisition, the director now directly owns 145,000 shares in the company, valued at approximately $198,650. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Inhibikase Therapeutics Stock Performance

NYSE:IKT opened at $2.42 on Friday. The firm’s 50-day moving average is $1.46 and its 200-day moving average is $1.53. The company has a market cap of $18.05 million, a price-to-earnings ratio of -0.84 and a beta of 1.32. Inhibikase Therapeutics, Inc. has a 52-week low of $0.80 and a 52-week high of $3.82.

Inhibikase Therapeutics (NYSE:IKT) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.08). Equities analysts predict that Inhibikase Therapeutics, Inc. will post -0.4 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered their price objective on shares of Inhibikase Therapeutics from $15.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, October 14th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Inhibikase Therapeutics stock. Armistice Capital LLC acquired a new stake in Inhibikase Therapeutics, Inc. (NYSE:IKT) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 589,575 shares of the company’s stock, valued at approximately $713,000. Armistice Capital LLC owned approximately 8.17% of Inhibikase Therapeutics as of its most recent filing with the SEC. 3.81% of the stock is currently owned by institutional investors.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.